

Amendments to the Claims:

Please amend claims 1, 6 and 8, and add new claims 34 and 35. This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 (currently amended): Fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety selected from the group consisting of thrombin, ~~fibronection~~, bacterial fibrinogen binding proteins, ~~basic fibrinogen-growth factor~~, integrins, and moieties derived from any member of this group, a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance, and a pharmaceutically active substance, wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

2 (canceled)

3 (previously presented): The conjugate of claim 1, wherein said substance capturing moiety is an antibody or a part thereof which specifically recognizes said pharmaceutically active substance.

4 (previously presented): The conjugate of claim 1, wherein said pharmaceutically active substance is selected from the group consisting of antibiotics, growth factors, receptors for tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, and imaging agents.

5 (original): The conjugate of claim 1, wherein said fibrin/fibrinogen-binding moiety and said substance capturing moiety are covalently bound.

6 (currently amended): Fibrin/fibrinogen-binding conjugate comprising

a fibrin/fibrinogen-binding moiety selected from the group consisting of thrombin, ~~fibronectin~~, bacterial fibrinogen binding proteins, ~~basic fibrinogen-growth factor~~, integrins, and moieties derived from any member of this group,

a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance,

wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

7 (canceled)

8 (currently amended): The conjugate of claim 6 wherein said fibrin/fibrinogen-binding moiety and said substance capturing moiety are covalently bound. [[.]]

9-11 (canceled)

12 (previously presented): The conjugate of claim 6 wherein said pharmaceutically active substance is selected from the group consisting of antibiotics, growth factors, receptors for tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, and imaging agents.

13-23 (canceled)

24 (previously presented): The conjugate of claim 6, wherein said substance capturing moiety is an antibody or part thereof which specifically recognizes said pharmaceutically active substance.

25 (previously presented): The conjugate of claim 1, wherein said substance capturing moiety is a receptor or a part thereof which specifically recognizes said pharmaceutically active substance.

26 (previously presented): The conjugate of claim 6, wherein said substance capturing moiety is a receptor or a part thereof which specifically recognizes said pharmaceutically active substance.

27 (previously presented): The conjugate of claim 1, wherein said pharmaceutically active substance is a wound healing substance.

28 (previously presented): The conjugate of claim 6, wherein said pharmaceutically active substance is a wound healing substance.

29 (previously presented): Fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety that is a nucleic acid, a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance,
wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

30 (previously presented): The conjugate of claim 29, wherein said substance capturing moiety is an antibody, a receptor or a part thereof which specifically recognizes said pharmaceutically active substance.

31 (previously presented): The conjugate of claim 29, further comprising a pharmaceutically active substance.

32 (previously presented): The conjugate of claim 31, wherein said pharmaceutically active substance is selected from the group consisting of antibiotics, growth factors, receptors for tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, wound-healing substances, and imaging agents.

33 (previously presented): The conjugate of claim 29, wherein said fibrin/fibrinogen-binding moiety and said substance capturing moiety are covalently bound.

34 (new): Fibrin/fibrinogen-binding conjugate comprising
a fibrin/fibrinogen-binding moiety selected from the group consisting of
thrombin, fibronectin, bacterial fibrinogen binding proteins, integrins, and moieties derived from
any member of this group,
a substance capturing moiety that is an antibody or a part thereof which
specifically recognizes a pharmaceutically active substance, and
the pharmaceutically active substance,
wherein said fibrin/fibrinogen-binding moiety is bound to said substance
capturing moiety.

35 (new): Fibrin/fibrinogen-binding conjugate comprising
a fibrin/fibrinogen-binding moiety selected from the group consisting of
thrombin, fibronectin, bacterial fibrinogen binding proteins, integrins, and moieties derived from
any member of this group,
a substance capturing moiety that is an antibody or a part thereof which
specifically recognizes a pharmaceutically active substance,
wherein said fibrin/fibrinogen-binding moiety is bound to said substance
capturing moiety.